ALNY vs BEAM · P/E 76, rev $1.29B vs rev $32.2M
Alnylam Pharmaceuticals Inc (ALNY) versus Beam Therapeutics Inc (BEAM) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported BEAM revenue for 2026-06-30 was $32.2M. Net income was -$217.0M. Revenue was up 1.5% from 2026-03-31 to 2026-06-30. BEAM currently screens at market cap $2.01B.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. BEAM currently screens at market cap $2.01B.
Not investment advice. Open the ALNY and BEAM stock pages for the full models.
Not investment advice.